Despite the tumor suppressive effect of AR in ER+ breast cancer,[32] bicalutamide[33] and enzalutamide[34] have shown potent clinical anti‐cancer activities in AR+ triple‐negative breast cancer (TNBC). This evidence concerns the gene AR and breast carcinoma.